Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Biobanking 2011 Forum


Published on

Programme for Pha

  • Be the first to comment

  • Be the first to like this

Biobanking 2011 Forum

  1. 1. Now in it’s 4th Year and in Partnership with ISBER, Global Register and pay byBiobanking has welcomed: Over 250 Attendees from Over175 Different Organisations 1st July to save up to £400 In partnershipBiobanking, Biomarkers and Bioethics:Establishing Partnerships and Improving Excellent content - very valuableBiobanking to Further Medical Research National Cancer InstituteConference: 27th-28th SeptemberBiomarkers & Personalised Healthcare Focus Day: 29th SeptemberVenue: Thistle Marble Arch, London, UK 19+ International Experts from TOP 3 Reasons to attend Europe’s leading industry forum: Industry, Academia and National Exclusive experiences and brand new case studies from industry, Biobanks academia and national biobanks – bringing together all the key stakeholders in one location Amelia Warner, Head of Clinical Pharmacogenetics, Merck and the I-PWG Officially partnered with ISBER to bring you the best programme, speakers and expertise. Come away with real take-home messages you Xavier Briand, Team Leader, Biobank, Novartis can use as soon as you get back! Anne Bahr, Deputy R&D and Data Privacy Officer, Brand new must-attend Focus Day on Biomarkers and Personalised sanofi-aventis Healthcare brings even more networking and learning opportunities! Arndt Schmitz, Senior Scientist, Bayer Attending Biobanking 2011 will ensure you can: Bas de Jong, Biobank Manager, Erasmus MC Tissue Bank and ISBER Improve sample storage capabilities and quality through collaboration with new expertise from Frans van der Horst, Chair, Dutch Collaborative Biobank and Georges Delphine Lagarde, Head of Biorepository, Roche Dagher of INSERM and the BBMRI Gillian Ellison, Tumour Genetics Capability Manager, Enable greater sharing of data and specimens and improve biomarker research by AstraZeneca establishing international biobanking standards and procedures with insights from Kim Myers, Agostino Steffan, Director Clinical Pathology Unit, National Director, U.S. National Cancer Institute Cancer Institute (Italy) Establish, develop and maintain a coordinated global biobanking network with new Martin Armstrong, Associate Director, Translational case studies from Xavier Briand, Team Leader, Biobank, Novartis and Delphine Lagarde, Medicine, Shire Pharmaceuticals Head of Basel Sample Repository, Roche Ruth Chadwick, Council Member, HUGO and Professor at Successfully navigating the bioethical complexities and constraints of sample Cardiff University collection and management to drive international harmonisation and enhance public education, with examples and experiences from international bioethics experts Dr. Nik Zeps, Nik Zeps, Research Group Leader, St John of God Prof. Ruth Chadwick and Prof. Bartha Knoppers Healthcare Increase the effectiveness of medical and biomarker research by improving sample Georges Dagher, Deputy Director, Clinical Research, INSERM quality through careful sourcing and management; discussions led by Bayer, AstraZeneca and Leader of Funding & Financing at BBMRI and Merck Antje Stratmann, Scientist, Bayer Emma Donald, Senior Research Scientist, AstraZeneca New for 2011: Biomarkers and Personalised Bartha Knoppers, Director, Centre of Genomics and Policy, McGill University Healthcare Focus Day Vincenzo Canzonieri, Co-Director, National Cancer Effective biomarker research is not only key to better medical Institute (Italy) development but also the gateway to personalised healthcare. That’s why this year’s event brings you: Kim Myers, Program Manager, U.S. National Cancer Institute • 5 exclusive plenary sessions dedicated to biomarkers & person alised healthcare Frans van der Horst, Chair, Dutch Collaborative Biobank • An open panel discussion with the day’s international Speaker faculty • Networking opportunities with peers and experts in this important field Lorenzo Memeo, Director of Pathology, Mediterranean Institute of OncologySponsors +44 (0)20 7368 9300 +44 (0)20 7368 9301
  2. 2. Conference Day One: 27th September 2011 08:30 Registration and Refreshments 12:20 Networking Lunch Break 09:00 Chairman’s Welcome 13:40 Meeting the Need for Standardised Biobanking: The U.S. National Cancer Institute’s Effort to Build a IMPROVING BIOBANKING GLOBALLY: PARTNERSHIPS, Centre for Biospecimen Science and Standards STANDARDS AND HARMONISATION • Justifying and building the centre and setting it’s mission statement and goals 09:10 Keynote Session: The Importance and Role of • Building upon the National Cancer Institute’s Collaborations in Biobanking Today history and experience in biospecimen • Giving a brief insight into the history and role of management and science the BBMRI • Identifying and prioritising the key areas in • Discussing how the tremendous progress in biobanking which need standardisation most the development of new analytical technologies • Using collaborations and partnerships to design represents a major challenge for the future the standards and spread the message development of medical research Kim Myers, Program Manager, U.S. National Cancer • Evaluating the need for an efficient solution Institute to providing trans-national access to high quality human biological samples CONSIDERATIONS AND TOOLS TO ENSURE THE EFFECTIVE • Looking at the BBMRI Expert Centres; private- AND EFFICIENT RUNNING OF YOUR BIOBANK public partnerships could be an adequate solution to these issues 14:20 Case Study: Effective Biobanking at Novartis - George Dagher, Deputy Director, Clinical Research, Current Activities and Future Directions INSERM and Leader of Funding & Financing at BBMRI • Coordinating studies and sample connection effectively 09:50 The Benefits, Need and Practical Viability of Local or • Assessing the pro’s, cons and general use of International Harmonised Biobanking automation in Novartis • Assessing the need for multi-centre research to • Tracking samples from source to storage to allow sample and data exchangeability research • Discussing the need for harmonisation and • Improving healthcare: human samples for research collaboration, and ISBER’s role in it - the Translational Research Initiative • Evaluating internal vs external quality assurance Xavier Briand, Team Leader, Biobank, Novartis (EQA) • Predicting the effects of EQA on overall biobank 15:00 Networking Coffee Break quality and credibility • Standardisation in tissue collections; locally and 15:30 Case Study: Developing and Maintaining the Roche across networks Sample Repository Bas de Jong, Biobank Manager, Erasmus MC Tissue • Assessing the challenges, changes and Bank and ISBER developments over the last 12 months • Evaluating the SOPs and techniques for sample 10:30 Networking Coffee Break collection and preparation for storage • Discussing the best methods of sample storage 11:00 Improving Sample Storage Capabilities and Quality • Using consent effectively and with minimal impact through Collaboration on the biorepository • Working together with a network of general Delphine Lagarde, Head of Basel Sample Repository, hospitals to increase the scale of biobanking to Roche increase quality and cost efficiency • Building a centralised facility to support small 16:10 Biobanking Requirements for Third Party Providers: scale participants An Industrial Perspective • Deploying user-friendly web based applications • Outsourcing of all biobanking, sample handling and (Bioresearch as a Service) to facilitate local biobank preparation is one model for the pharmaceutical initiatives • Adopting generally accepted ontological sector frameworks for information input to ensure • Highlighting and discussing the main requirements optimal down stream data utilisation and accessibility • Assessing the expectations of providers from an Frans van der Horst, Chair, Dutch Collaborative industry (personal) perspective Biobank • Working together in order to achieve maximum biobanking efficiency and effectiveness 11:40 Speaker’s Panel Session: Martin Armstrong, Associate Director, Translational The Purpose, Benefits and Viability of Collaborations Medicine, Shire Pharmaceuticals and Partnerships in Biobanking Today In this interactive panel session, Speaker’s from this 16:50 Chairman’s Closing Comments morning’s “Collaborations” section of the event will take your questions – please come prepared to put your 17:00 Close of Day One questions to the panel! • Evaluating the role collaborations and partnerships play • Discussing examples of existing successful partnerships • Educating the public through collaboration in the media Panellists: George Dagher, Deputy Director, Clinical Research, Very nice presentations with INSERM and Leader of Funding & Financing at BBMRI Frans van der Horst, Chair, Dutch Collaborative spot on subjects. Very good sessions Biobank Bas de Jong, Biobank Manager, Erasmus MC Tissue Erasmus MC Tissue Bank Bank and ISBER
  3. 3. Conference Day Two: 28th September 2011 08:30 Registration and Refreshments 12:20 Networking Lunch 09:00 Chairman’s Welcome 13:40 Assessing the Viability and Future of DNA Biobanking in Today’s World ENSURING HIGH QUALITY SAMPLE COLLECTION, STORAGE • Discussing whether DNA sample storage is still AND RETRIEVAL TO FACILITATE MEDICAL RESEARCH important with the developments in today’s sequencing and analytical technology 09:10 Keynote Session: Successfully Navigating the • Evaluating various storage techniques for DNA Bioethical Complexities and Constraints of Sample samples Collection and Management • Debating whether original informed consent covers • Looking at the bigger picture: a global, social lack DNA collection and analysis of data privacy • Discussing whether the patient should be informed • Assessing how this wider attitude impacts the of other discovered conditions biobanking world Amelia Warner, Head of Clinical Pharmacogenetics, • Evaluating the regulatory constraints and gaps for Merck biospecimen data privacy • Discussing the effect new technology has had on UTLISING COST-EFFECTIVE PARTNERSHIPS TO ENHANCE bioethics, and what this means for biobanking THE QUALITY OF PRODUCT DELIVERY Ruth Chadwick, Council Member, HUGO and Professor at Cardiff University 14:20 Research Biobanking as a Facilitator for Biomarker Discovery 09:50 Getting it Right: Managing the Ethics of Biospecimen • Ensuring compliance and best practice with a solid Use in Biomedical Research concept • Navigating the “minefield” of informed consent • Dealing with the daily challenge of operations in a • Understanding the expectations and obligations of fast changing environment - providing fit for returning results to patients purpose samples just in time • Commercialising outcomes from human • Improving collaboration between clinical academia, biospecimens research biotechs and pharma industry by identifying • Managing the public/private interface (or How I mutual win-wins Learned to Stop Worrying and Love the Research) • Validating initial findings in translational research – Nik Zeps, Research Group Leader, St John of God bed-to-benchside and back Healthcare Arndt Schmitz, Senior Scientist, Bayer Antje Stratmann, Scientist, Bayer 10:30 Networking Coffee Break 15:00 Networking Coffee Break 11:00 Creating a Thorough and Useful Consent Form to Allow Future Use of Samples 15:30 Standards in Pre-Storage Sample Analytics and their • Ensuring compliance with personal data Effect on Quality protection regulations, including the EU • Research done to define quality factors associated personal data protection directive and with the pre-acquisition phase guidelines related to biomedical research and • Process changes in the pre-acquisition phase that pharmacovigilance present themselves as barriers to • Complying with human samples collection implementation of desired strategies regulations, and international texts relating to • Impacts of lag times time between tissues being biobanking without a blood supply and freezing • Ensuring that samples and data can be re-used • Recommended analytics for repository samples • Managing samples once collected: how should upon initial acceptance they be coded? How can we manage consent Emma Donald, Senior Research Scientist, withdrawal? AstraZeneca Anne Bahr, Deputy R&D and Data Privacy Officer, sanofi-aventis 16:10 Quality Control of Tissues: The Pathologist’s Perspective IMPROVING THE RUNNING OF YOUR BIOBANK THROUGH • Defining SOP’s in tissue collection and storage EFFECTIVE LOGISTICS AND TECHNOLOGY • Assessing the quality and integrity of the tissues • Aliquoting tissue samples and defining MTA 11:40 Bioethics Open Panel Discussion: Ensuring Good • Debating the pro’s and cons of FFPE vs. Frozen Tissues Ethical Practice in Biobanking and Research Vincenzo Canzonieri, Co-Director, Pathology Dpt. • Negotiating informed consent – reach, coverage & Resp. Biobank, National Cancer Institute 9Italy) flexibility Lorenzo Memeo, Director, Pathology Dpt., Resp. • Return to patients: should biobanks play an active Biobank, Mediterranean Institute of Oncology role? • Sample collection and analysis: evaluating good 16:50 Chair’s Closing Comments ethical practice • Topics from the Floor 17:00 Close of Main Conference Panellists: Ruth Chadwick, Council Member, HUGO and Professor at Cardiff University Nik Zeps, representative, Australian Health Ethics Committee and the Ethics and Policy Great to have a day of practical projects & big Committee of the International Cancer Genome Consortium Bartha Knoppers, Director, Centre of Genomics and Policy, McGill University and Canada Research Chair in Law and Medicine pharma. Extremely valuable Chaired by the Chair of the Day Genentech
  4. 4. Post-Conference Focus Day: 29th September 2011Biomarkers & Personalised Healthcare08:30 Registration and Refreshments09:10 How Biobanking Enables Pre-Clinical Biomarker Validation • Biomarker concepts - prognostic, pharmacodynamic and predictive markers and their respective value and sample needs • Utilising central biobanking as enabling technology supporting a project portfolio • Successfully validating pre-clinical biomarker assays for the clinic, what can animal models contribute • Establishing fruitful collaborations with biotechs and academic clinicians providing today’s gold standard of care • The new holy grail for pharma oncology development projects - circulating tumor cells? Arndt Schmitz, Senior Scientist, Bayer Antje Stratmann, Scientist, Bayer09:50 The Importance of Biomarkers: Facilitating Drug Discovery and Development • Evaluating the importance of biomarkers in today’s research • Highlighting how biomarker discovery can be aided by effective biobanking • Discussing the role of biomarkers in translational medicine • Overcoming the major hurdles of biomarker discovery and validation Vincenzo Canzonieri, Co-Director, Pathology Dpt., Resp. Biobank, National Cancer Institute (Italy) Lorenzo Memeo, Director, Pathology Dpt., Resp. Biobank, Mediterranean Institute of Oncology Agostino Steffan, Director Clinical Pathology Unit, National Cancer Institute (Italy)10:30 Networking & Refreshments11:00 Effective Analysis of Tumour Samples for Personalised Healthcare and Biomarkers: a User Case Study • Evaluating what benefits personalised healthcare approaches have brought to oncology patients • Identifying the key difficulties in biomarker analysis in oncology • Emphasising how important biobank accessibility and access to samples is solving these difficulties • Using new technology to reduce the occurrence of similar challenges in the future Gillian Ellison, Tumour Genetics Capability Manager, AstraZeneca11:40 Panel Discussion: Biomarkers, Biobanking and Collaborations In this interactive panel session, Speaker’s from today’s biomarker and personalised healthcare focus day will take your questions – please come prepared to put your questions to the panel! • Discussing the role biobanking plays in biomarker research • Identifying how biobanks could facilitate research • Overcoming common hurdles in biomarker discovery & validation • Translating biomarkers into the clinic Panellists: Arndt Schmitz, Senior Scientist, Bayer Gillian Ellison, Tumour Genetics Capability Manager, AstraZeneca Amelia Warner, Head of Clinical Pharmacogenetics, Merck12:20 Networking Lunch13:40 The Role of Companion Diagnostics and Personalised Healthcare in Drug Development: Improving Efficacy and Reliability • Discussing the role companion diagnostics can play in drug development • Assessing the advantages and disadvantages of using companion diagnostics • Incorporating companion diagnostics seamlessly into pre-clinical development • Evaluating the clinical viability Amelia Wall Warner, Head of Clinical Pharmacogenomics, Merck14:20 Biomarkers as a Gateway to Personalised Medicine • Assessing what stage we are at in the journey towards personalised healthcare • Discussing the impact of the change from blockbuster drugs to patient-centric healthcare • Analysing the importance and use of stratified trials and medicine • Highlighting how biomarker research (and thus biobank sample quality) is key Birgitte Søgaard, Divisional Director, Clinical Pharmacology and Translational Medicine, Lundbeck15:00 Close of Focus Day +44 (0)20 7368 9300 +44 (0)20 7368 9301
  5. 5. Sponsors & in 1980, Marken is focused on supporting the premium logistics of Pharmaceutical, Biotechnology KBioscience is a UK based technology company with one businessand clinical service companies. Through our strategically placed offices we manage the collection, transport unit focused on Drug Discovery products, including Covaris Adaptiveof specimens, and distribution of temperature sensitive clinical trial supplies. Additionally through our depot Focused Acoustics (AFA) technology. Adaptive Focused Acousticsnetwork we support the storage and distribution of life science assets. Our team members and network of (AFA) technology empowers many scientific disciplines to develop newfacilities bridge the distance between patients and the essential resources of life science companies. processes using isothermal and non-contact processes, including acoustic homogenization and acoustic dissolution. Main applications forMarken understands the specialized and dynamic needs of our industry; we retain our global agility by the AFA technology are Compound Dissolution, (Pre-)Formulation andcontinuously investing in our people, technologies and global installations to better support our clients. tissue disruption (AMDEtox, DMPK, RNA and biomarker extraction).People With over 400 people in 25 offices spanning the world, Marken has the expertise to ship globally and In Compound management AFA offers greatly improved dissolutiondeliver locally to investigator sites or directly to patients. speeds and standardizes the dissolution process. In Screening AFA can drastically improve compound re-dissolution and lowering CV’s byTechnologies Our state of the art management, tracking and information systems are second to none efficient assay mixing. KBiosciences further offers several technologiesoffering our clients real time visibility to the last mile. From hand to hand our chain of custody reflects our for sealing, piercing and cutting of seals and plates. Products arededication to supporting and exceeding our client’s expectations. standard heat- and pressure sealers, as well as special laser sealing (pre)piercing and cutting machines.The combination of Expertise, Agility, and Resources are complemented by our dedication to supportingour clients, their patients and the many lives that depend on our services. Company general contact details: Unit 7, Maple Park, Essex road, Hoddesdon, EN11 0EX, United KingdomCompany general contact details: Tel +44 (0) 1992 470 757Unit 3, Hogarth Business Park, Burlington Lane, Chiswick, London W4 2TX, United Kingdom Fax +44 (0) 8700 511302Tel: +44 203 249 7400 +44 203 249 7322 Media Partners Sponsorship & Exhibition Opportunities Maximise Your Involvement: Sponsorship and Exhibition Opportunities The biomolecular screening portal Pharma IQ’s Global Pharmaceutical Global Biobanking 2011 is attended by senior officials and decision-makers from industry, academia, institutes and national biobanks, bringing together buyers and suppliers in one location. In addition to this, Global Biobanking is the only Conference in Who Should Attend? Europe to partner with ISBER. Senior Vice President, Vice President, Focused and high-level, the event will be an excellent Executive Director, Director, Associate platform to initiate new business relationships. With tailored networking, sponsors can achieve the face-to-face Director, Head and Manager from: contact that overcrowded trade shows cannot deliver. • Independent Biobanks • Pharmacogenomics Exhibiting and Sponsorship options are extensive, and • Pharmaceutical • Pathology • Biotech • Genomics packages can be tailor-made to suit your individual • Medical Research Institute • Translational Medicine company’s needs. Most packages include complimentary • Academia • Personalised Medicine entry passes, targeted marketing to industry officials and • Related government officials • Lab Management executives, and bespoke networking opportunities. In the following departments: • Inventory Management • Research & Development • Molecular Technologies Other features of sponsorship include: • Biobanking • Biologics Research • Biorepository • Data Privacy/Protection/ • Prominent exhibition space in the main conference • Biological Sample Security Officers networking area Management • Quality Control and Quality • Participation in comprehensive pre-event marketing • Biosample Management Management campaigns • Tailored marketing strategies to suit your organisation’s size, capabilities and individual requirement About Pharma IQ For more information and to discuss the right opportunity, contact Gal Cohen on +44 (0)207 368 9300 or sponsorship@ Continue your learning experience with Pharma IQ online. As well as playing host to a series of global events where leading industry experts and thought leaders share their experience, knowledge and strategic thoughts, Pharma IQ also offers an online community for pharma & biotech professionals. Join now to network with your peers and access exclusive videos, podcasts and presentations from this and other Pharma IQ events. Join the community: +44 (0)20 7368 9300 +44 (0)20 7368 9301
  6. 6. Global Biobanking 2O11 5 WAYS TO REGISTER Freephone: 0800 652 2363 or Conference: 27th-28th September Biomarkers & Personalised Healthcare Focus Day: 29th September +44 (0)20 7368 9300 Venue: Thistle Marble Arch, London, UK Fax: +44 (0)20 7368 9301 To speed registration, please provide the priority code located on the mailing label or in the box below. Post: your booking form to My registration code is: PDFW IQPC Ltd. 129 Wilton Road, Please contact our database manager on +44(0) 207 368 9300 or at quoting the registration code above to London SW1V 1JZ inform us of any changes or to remove your details. Online: Academia and Biobanks Email: Packages Register and Pay by Register and Pay by Register and Pay by Standard Price 1st July* 29th July* 2nd September* Conference + Focus Day £748+VAT £798+VAT £848+VAT £998+VAT Join our Global Biobanking event on Save £250 Save £200 Save £150 £499+VAT £549+VAT £599+VAT £699+VAT Conference Only Save £ 200 Save £150 Save £100 Focus Day Only £299+VAT £299+VAT £299+VAT £299+VAT Team Discounts* Industry IQPC recognises the value of learning in teams. Groups of 3 or more Packages Register and Pay by Register and Pay by Register and Pay by Standard Price booking at the same time from the same company receive a 10% 1st July* 29th July* 2nd September* discount. 5 or more receive a 15% discount. 7 receive a 20% discount. £1,098+VAT £1,198+VAT £1,298+VAT £1,498+VAT Conference + Focus Day Save £400 Save £300 Save £200 Only one discount available per person. £799+VAT £899+VAT £999+VAT £1,099+VAT Conference Only Save £ 300 Save £200 Save £100 Venue & Accommodation Focus Day Only £399+VAT £399+VAT £399+VAT £399+VAT VENUE: Thistle Marble Arch Solution Providers Bryanston Street, Marble Arch, London W1H 7EH Packages Register and Pay by Register and Pay by Register and Pay by Standard Price 1st July* 29th July* 2nd September* Phone: 0871 376 9027 Fax: 0871 376 9127 ACCOMMODATION: £1,798+VAT £1,848+VAT £1,898+VAT £2,048+VAT Conference + Focus Day Save £250 Save £200 Save £150 For Thistle Marble Arch Tel: +44 (0)871 376 9027 select option 1, £1,399+VAT £1,449+VAT £1,499+VAT £1,599+VAT or email: . Always Conference Only Save £ 200 Save £150 Save £100 quote promotional code GA1. Prices from £130 + vat including Focus Day Only £449+VAT £449+VAT £449+VAT £449+VAT breakfast. Or for a further selection of London. hotels search *To qualify for discounts, payments must be received by the early bird registration deadline. Early booking discounts are not valid in conjunction with any other offer. UK VAT is charged at 20%. VAT Registration # GB 799225967 Free Online Resources To claim a variety of articles, podcasts and other free resources please Delegate Details visit Please photocopy for each additional delegate 6 Mr 6 Mrs 6 Miss 6 Ms 6 Dr 6 Other Digital Conference On CD-ROM First Name Family Name A digital version of the conference proceedings, including all presentations, is available to buy. Job Title 6 I cannot attend the event, please send me the CD Rom priced at Tel No. £599 plus VAT Email Recent digital conferences available - £599 plus VAT each 6 Yes I would like to receive information about products and services via email 6 Biobanking 2009 Organisation 6 Compound Management 2009 Nature of business 6 Disposables for Biomanufacturing 2009 6 Cool Chain Europe 2010 Address Postcode Country Please send me conference materials indicated above. Telephone Fax I have filled out credit card details below Approving Manager For further information Name of person completing form if different from delegate: Please call: 0207 368 9300 or email: Signature I agree to IQPC’s cancellation, substitution and payment terms Terms and Conditions Special dietary requirements: 6 Vegetarian 6 Non-dairy 6 Other (please specify) Please read the information listed below as each booking is subject to IQPC Ltd standard terms and conditions. Return of this email will indicate that you accept these terms. Please indicate if you have already registered by Phone 6 Fax 6 Email 6 Web 6 Payment Terms Upon completion and return of the registration form full payment is required no later than 5 Please note: if you have not received an acknowledgement before the conference, please call us to confirm your booking. business days from the date of invoice. Payment of invoices by means other than by credit card, or purchase order (UK Plc and UK government bodies only) will be subject to a £49 (plus VAT) per delegate processing fee. Payment must be received prior to the conference date. We reserve the right to refuse admission to the confer- Payment Method ence if payment has not been received. IQPC Cancellation, Postponement and Substitution Policy You may substitute delegates at any time by providing reasonable advance notice to IQPC. For any cancellations received in writing not less than eight (8) Total price for your Organisation: (Add total of all individuals attending): days prior to the conference, you will receive a 90% credit to be used at another IQPC conference which must occur within one year from the date of issuance of such credit. An administration fee of 10% of the contract fee Card Number: VISA 6 M/C 6 AMEX 6 will be retained by IQPC for all permitted cancellations. No credit will be issued for any cancellations occurring within seven (7) days (inclusive) of the conference. 6666666666666666 In the event that IQPC cancels an event for any reason, you will receive a credit for 100% of the contract fee paid. You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur within one year from the date of cancellation. Exp. Date: 6 6 6 6 Sec: 6 6 6 6Conference code 13647.004 In the event that IQPC postpones an event for any reason and the delegate is unable or unwilling to attend in on the rescheduled date, you will receive a credit for 100% of the contract fee paid. You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur within one year from the date of Name On Card: Signature: postponement. Except as specified above, no credits will be issued for cancellations. There are no refunds given under any circumstances. Billing Address (if different from below): IQPC is not responsible for any loss or damage as a result of a substitution, alteration or cancellation/postpone- ment of an event. IQPC shall assume no liability whatsoever in the event this conference is cancelled, resched- City/County/Postcode Cheque enclosed for: £ (Made payable to IQPC Ltd.) uled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any other event that renders performance of this conference impracticable, illegal or impossible. For purposes of this clause, a fortuitous event shall include, but not be limited to: war, fire, labour strike, extreme weather or other emergency. Please note that while speakers and topics were confirmed at the time of publishing, circumstances beyond the (Please quote 13647.004 with remittance advice) control of the organizers may necessitate substitutions, alterations or cancellations of the speakers and/or topics. As such, IQPC reserves the right to alter or modify the advertised speakers and/or topics if necessary without any IQPC Bank Details: HSBC Bank, 67 George Street, Richmond Surrey, TW9 1HG. Sort Code: 40-38-18 Account No: 51304143 Swift liability to you whatsoever. Any substitutions or alterations will be updated on our web page as soon as possible. Code: MIDLGB2112V IBAN Code: GB59MIDL40381851304143 Account Name: International Quality & Productivity Centre Ltd. Discounts All ‘Early Bird’ Discounts require payment at time of registration and before the cut-off date in order to receive any discount. Any discounts offered whether by IQPC (including team discounts) must also require payment at the time of registration. All discount offers cannot be combined with any other offer PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE